Kornimate/medical-research-clean huggingface dataset:
life quality determinant assessment of fibromyalgia patients

Conditions: Fibromyalgia

Summary: the primary purpose is the evaluation of life quality of fibromyalgia patients. the investigators' main hypothesis includes the role of geographical, sociological, psychological and physical activity on life quality.


Eligibility criteria:
inclusion criteria: * age group : 20 to 60 * male or female * american college of rheumatology criteria * social security beneficiary * informed consent of the patient * patient informed of the medical examination prior to inclusion * patient residing in the bas-rhin area exclusion criteria: * no medical objections to performing a stress test * any cardio-respiratory and musculoskeletal affection preventing physical activity * any particular clinical form disease * patient in situation of exclusion * subject incapacity to understand informed consent * patient deprived of freedom or under the protection of a conservator * pregnancy or breast-feeding

Keywords: quality of life physical activity
evaluation of tnf-α blockade effect in patients with severe cutaneous adverse drug reactions

Conditions: Drug Hypersensitivity

Summary: severe skin adverse drug reactions can result in death. toxic epidermal necrolysis (ten) has the highest mortality (30-35%); stevens-johnson syndrome and transitional forms correspond to the same syndrome, but with less extensive skin detachment and a lower mortality (5-15%). hypersensitivity syndrome, sometimes called drug reaction with eosinophilia and systemic symptoms (dress), has a mortality rate evaluated at about 10%. the aims of this project are (1) to compare the effect of treatment between systemic steroid and anti-tnf-α. including skin healing time, beginning of re-epithelialization time, internal organ recovery time, mortality rate, adverse events and (2) to investigate the molecular mechanism of severe cutaneous adverse reaction after anti-tnf-α treatment.

severe cutaneous adverse drug reactions, including toxic epidermal necrolysis (ten), stevens-johnson syndrome(sjs), drug reaction with eosinophilia and systemic symptoms (dress) is a life threatening disease. there is no gold standard in the therapy of scar. treatment with high dose systemic corticosteroids is controversial. although there have been recent reports of success with various therapies such as plasmapheresis and high-dose intravenous immunoglobulins, their efficacy is not yet proven. assessment of these therapies is difficult because of their non-specific immunosuppressant or immunomodulating modes of action. recent studies have shown evidence of the pathogenetic importance of tumour necrosis factor (tnf)-a, suggesting a new therapeutic approach in selective blockade of tnf-a using specific antibodies. we report successful treatment ten using monoclonal igg anti-tnf-antibodies. the aims of this project are (1) to compare the effect of treatment between systemic steroid and anti-tnf-α. including skin healing time, beginning of re-epithelialization time, internal organ recovery time, mortality rate, adverse events and (2) to investigate the molecular mechanism of severe cutaneous adverse reaction after anti-tnf-α treatment.

Eligibility criteria:
inclusion criteria: 1. male or female patient with clinical and pathological diagnoses of severe cutaneous adverse drug reactions such as stevens-johnson syndrome, toxic epidermal necrolysis or durg reaction with eosinophilia and systemic symptoms. 2. male or female patient aged more than 4 years. 3. inform consent obtained. exclusion criteria: 1. pregnant or breastfeeding female. 2. allergic to any anti-tnf-α biological product. 3. active or latent tuberculosis confirmed with chest x-ray. 4. severe active infection and septicemia. 5. active hepatitis b or c carrier. 6. suspected hiv carrier with cd4 count less than 200. 7. patient with poor compliance or with safety concerns judged by investigator.

Keywords: scar anti-tnf-a
internet-based, naturalistic evaluation of tolerability and individual patient target pressures with bimatoprost 0.03% in glaucoma

Conditions: Glaucoma, Open-Angle

Summary: the purpose of this study is to evaluate the range of target iops set for glaucoma patients starting monotherapy with bimatoprost and to evaluate patient and physician satisfaction with bimatoprost in "real-world" settings


Eligibility criteria:
inclusion criteria: * patients with either open-angle glaucoma or ocular hypertension were eligible if they needed bilateral iop reduction beyond what was achieved with their current medication, or if they were intolerant of other iop-lowering medications.
pregnancy exposure registry for avonex (interferon beta-1a)

Conditions: Prenatal Exposure Delayed Effects; Multiple Sclerosis; Pregnancy

Summary: the primary objectives of the study were to prospectively record and analyze birth defects and spontaneous fetal losses in women with multiple sclerosis (ms) exposed to avonex within approximately 1 week of conception or during the first trimester of pregnancy, where the outcome of the pregnancy was unknown prospectively and to prospectively record and analyze pregnancy outcomes in an exploratory fashion of women with ms who stopped therapy, but who may have been exposed to avonex with approximately 1 week of conception or during the first trimester of pregnancy.


Eligibility criteria:
key inclusion criteria: * have been exposed to avonex within approximately 1 week of conception or during the first trimester of pregnancy. * provide sufficient information to determine that the pregnancy is prospectively registered (i.e., the outcome of pregnancy must be unknown prospectively). * provide verbal consent to participate in the registry. * verbally provide contact information for herself, her hcp, and the infant's hcp (if applicable). note: other protocol defined inclusion/exclusion criteria may apply.

Keywords: avonex pregnancy
repetitive assessement of scores in patients on dual antiplatelet therapy

Conditions: Dual Anti-platelet Therapy

Summary: patients treated with percutaneous coronary intervention (pci) require dual antiplatelet therapy (dapt). preliminary assessment of the precise-dapt score is mandatory in order to assess the risk of bleeding while on dapt. the score takes into consideration age, creatinine clearance, haemoglobin, white-blood-cell count and previous spontaneous bleeding. one should consider, however, that some of the variables included in the precise-dapt score might change with time. as a consequence, the precise-dapt score should not be considered a static score as it might vary after the initial computation. it remains unknown, however, if the delta precise-score, reflecting the change in score between baseline and follow-up, might predict more reliably the long-term bleeding risk of pci patients.

the re-score registry is a multicenter study aimed at comparing the predictive value of the precise-dapt score assessed at time of discharge vs. the delta precise-dapt score, as assessed every 3 months in pci patients receiving dapt. the primary end-point of the study is the occurrence of bleeding, as defined according to the criteria of the bleeding academic research consortium (barc), either in the whole study population or in men vs women.

Eligibility criteria:
inclusion criteria: all patients undergoing percutaneous coronary intervention and treated with dual antiplatelet therapy for at least 3 months exclusion criteria: contraindications to dual antiplatelet therapy lasting more than 3 months
effects of shockwave therapy on crouched gait due to hamstring flexibility in cerebral palsy children

Conditions: Cerebral Palsy

Summary: randomized controlled trial will be conducted on thirty-two cerebral palsy children in punjab special school. spastic diplegic cp children with gmfcs level iii, iv, v with age range of 6 to 12. these children have limited range of hamstring muscles. assessment will be measured pre and post treatment by goniometer of crouched gait in standing and lying on couch. crouched gait will be measured by knee flexion in standing and lying. to measure hamstring flexibility rom of knee extension is measured with 90 flexion at hip joint. spasticity in this study will be assessed by gmfm-88 and modified ashworth scale.

shortwave therapy, stretching and orthotics will be provided to group a. shock wave session will be provided for 20 minutes thrice a week. five days, five minutes with 30 seconds sustained stretch will be provided and than orthotics will be used to obtained the sustained effect. in group b spastic diplegic children just given stretching with strengthening and orthotics. we provide sustained 30 seconds stretch with 30 seconds rest for 5 minutes and followed with forty repetition of hip flexor and knee flexors and range will be maintained by applying orthosis.

Eligibility criteria:
inclusion criteria: * children with gmfcs level i, ii \& iii. * passive range of motion of knee extension is limited to 20 degree with hip 90 degree. * age between 6 to 12 years. exclusion criteria: * children with epileptic history * previous muscular lengthening technique applied * previous history of botox injection used.

Keywords: cerebral palsy shock wave hamstring flexibility crouched gait
a predictive model based on quantitative fecal immunochemical test can stratify the risk of crc in an organized screening program

Conditions: Colorectal Cancer Screening

Summary: the covid-19 pandemic has disrupted every aspect of medical care, including screening programs and preventive medical care . organized fit-based colorectal cancer screening programs make no exception, since their efficacy depends on a multi-tiered series of interventions that were hampered by the pandemic at multiple levels. in detail, the first level of intervention, namely population based fit tests distributed to the population, has seen a dramatic decrease of number of tests performed for both organizational reasons (i.e. less personnel deployed to testing sites) and for failure to present fecal samples from patients for fear of contagion or impossibility to reach the drop-off sites for state-imposed limitations. secondly, the referral of fit positive patients to subsequent colonoscopy was stopped or delayed since endoscopy services have been undergoing only emergent and urgent procedures. thirdly, patients diagnosed with advanced neoplasia or cancer have seen their endoscopic or surgical removal procedures delayed or canceled . regarding post-fit colonoscopy workup, european screening guidelines recommend a 30-day maximum span between a positive fit test and subsequent colonoscopy. it is well known that any delay in post-fit+ colonoscopy results in an increase in advanced neoplasia and colorectal cancer, that reaches dramatic levels after 6 months . our purpose is to develop and validate, using the quantitative level of faecal hemoglobin found in fit, a simple scoring system to effectively sub-stratify crc risk of fit positive patients.


Eligibility criteria:
inclusion criteria: * all fit+ patients awaiting to be scheduled for colonoscopy workup. patients will be invited to undergo a colonoscopy, and depending on its outcome, patients are referred for surgery, postcolonoscopy surveillance, or further rounds of fit. exclusion criteria: * individuals with a prevalent diagnosis of crc are excluded from the program, as well as patients that have already undergone a high quality colonoscopy.

Keywords: fecal immunochemical test colorectal cancer screening program
hypertension in hemodialysis patients (aim 3)

Conditions: Hemodialysis; Hypertension; Left Ventricular Hypertrophy

Summary: we will directly test the hypothesis that an initial strategy of lisinopril-based therapy will be more effective than atenolol-based therapy in causing regression of left ventricular hypertrophy (lvh) over one year in patients with hemodialysis hypertension despite similar degree of bp reduction.

this is a parallel group, active control, single-center, open-label, randomized controlled trial comparing the safety and efficacy of initial therapy with an angiotensin converting enzyme (ace) inhibitor (lisinopril) vs. beta-blocker therapy (atenolol) each administered three times weekly after dialysis.

Eligibility criteria:
inclusion criteria: 1. patients on chronic hemodialysis for \> 3 mos. 2. compliance with hemodialysis treatments as defined by less than one missed dialysis per month 3. hypertension as diagnosed by ambulatory blood pressure monitoring (abpm) \>135/75 mm hg after participation in the ultrafiltration (uf) trial, or those on no antihypertensive medications but unwilling to do uf trial. 4. presence of lvh on echocardiogram defined as left ventricular mass index (lvmi) \>104 g/m2 in women and \>116 g/m2 in men. 5. willingness to give informed consent. exclusion criteria: 1. vascular event (stroke, myocardial infarction or limb ischemia requiring bypass) within previous six months 2. noncompliance with hemodialysis treatments 3. known drug abuse 4. chronic obstructive pulmonary disorder (copd) requiring home oxygen 5. congestive heart failure class iii or iv. 6. body mass index \> 40 kg/m2. 7. known contraindication to atenolol (severe heart failure, bradycardia, bronchial asthma, intolerance or allergy) or lisinopril (cough, pregnancy, intolerance or allergy)

Keywords: hemodialysis hypertension left ventricular hypertrophy
evaluation of inadequate response to ultrasound-guided subacromial corticosteroid injection in shoulder impingement syndrome

Conditions: Impingement Syndrome

Summary: the aim of this study is to investigate the impact of central sensitization in patients with shoulder impingement syndrome who have shown an inadequate response to ultrasound-guided subacromial corticosteroid injection. additionally, the patients' pain perception and emotional state will be evaluated, and the relationships between these factors and the treatment response will be analyzed.

seventy-two patients aged 18-75, who applied to the physical therapy and rehabilitation outpatient clinic at beylikdüzü state hospital, diagnosed with shoulder impingement syndrome based on magnetic resonance imaging (mri), and who received ultrasound-guided corticosteroid injection, will be included in the study. no additional interventions or procedures will be performed for the research. these patients, who were previously assessed and treated in the outpatient clinic, will be invited for a follow-up examination at the 4th week after the injection. during the follow-up, their response to the treatment will be evaluated using the visual analog scale (vas). a reduction of less than 50% on the vas by the end of the 4th week will be considered an inadequate response. patients with inadequate and good responses will be divided into two groups and assessed for central sensitization, pain perception, and emotional state. central sensitization will be evaluated using the central sensitization inventory (csi), and hyperalgesia will be assessed using an algometer to measure pressure-pain threshold. additionally, the pain catastrophizing scale and the hospital anxiety and depression scale will be used to determine the patients' emotional state and pain perception.

Eligibility criteria:
inclusion criteria: * patients aged 18-65. * diagnosed with shoulder impingement syndrome. * received ultrasound-guided subacromial corticosteroid injection. * experienced shoulder pain for at least 6 months. exclusion criteria: * history of surgery or fracture in the shoulder or related areas. * presence of an active infection. * received shoulder injection within the last 6 months. * underwent physical therapy for the shoulder in the last 6 months. * presence of other musculoskeletal or neurological conditions that could cause shoulder pain (e.g., cervical disc herniation, stenosis, moderate to severe osteoarthritis, adhesive capsulitis, rheumatologic pathologies, infectious joint diseases).
study to evaluate the leish-111f + mpl-se vaccine in the treatment of mucosal leishmaniasis

Conditions: Leishmaniasis, Mucocutaneous

Summary: the purpose of this study is to evaluate the safety of the leish-111f + mpl-se vaccine given as three injections every 28 days at each of three dose levels of leish-111f protein, in combination with standard pentavalent antimony therapy in adult patients with mucosal leishmaniasis.

mucosal leishmaniasis is a disfiguring and possibly fatal infection. all available medical therapies require weeks of treatment and cause significant toxicity. in peru, the standard therapy is daily intravenous (iv) pentavalent antimony (20 mg/kg/day) for 28 days. it appears that leishmania infections can be eliminated by t helper 1 immune responses. these findings argue that a vaccine that augments mucosal leishmaniasis patients' t helper 1 responses will eliminate the infection and disease. this study is a phase 1, randomized, double-blind, placebo controlled, sequential dose-escalating trial to evaluate the safety and immunogenicity of three injections of 5, 10, or 20 μg of leish-111f protein + 25 μg of mpl-se adjuvant given at 4 week intervals as an adjunct to standard chemotherapy with pentavalent antimony (20 mg/kg/day for 28 days) in patients with mucosal leishmaniasis.

Eligibility criteria:
inclusion criteria: * patients with mucosal leishmaniasis confirmed by a positive smear, in vitro culture or pcr test exclusion criteria: * mucosal leishmaniasis must not involve the vocal cords or cause respiratory distress, and there must be no evidence of other disease.

Keywords: leishmaniasis subunit vaccine therapeutic t-cell pentavalent antimony
clinical performance of restorative materials in primary teeth

Conditions: Caries; Dentin; Dental Caries

Summary: the purpose of this study is to evaluate and compare the clinical performance of dental restorative materials in class ii cavities of primary molar teeth

restorations will be placed on four primary molar teeth with proximal caries, in a split mouth design. 100 patients will be included in the study. the teeth will be randomized into four groups according to the restorative materials. group 1: adhesive agent+ compomer (dyract ap, dentsply detrey, konstanz,germany) group 2: primer + resin modified glass ionomer (vitremer, 3m espe, u.s.) group 3: adhesive agent + giomer (beautifil ii, (shofu dental, tokyo, japan) group 4: amalgam (permite amalgam, sdi limited, bayswater, australia) the restorations will be evaluated at baseline, 3., 6., 12. months for the first year, and at every 6 months for 5 years. the modified us public health service criteria (secondary caries, marginal integrity, marginal discoloration and retention) will be used for clinical evaluation of restorations. the data will be analysed statistically using wilcoxon test, chi square test and the kaplan-meier survival method will be used to estimate survival percentages.

Eligibility criteria:
inclusion criteria: * patients and parent of the patients who accept to participate and sign the informed consent * patients who have at least four first and/or second primary molars with proximal caries that require class ii restorations * teeth that have healthy lamina dura and periodontal ligament * teeth that have caries lesions extending no more than the outher half of dentin radiographically exclusion criteria: * patients and parent of the patients who don't accept to participate and sign the informed consent * teeth that are previously restored * patients who are uncooperative * teeth that doesn't have proximal or occlusal contacts with adjacent healthy teeth * patients who have bruxism, skeletal or dental malocclusion * teeth that have developmental defects or anomalies

Keywords: restorative materials primary teeth children
rapid diagnosis of severe respiratory tract infectious diseases and screening of biomarkers for stratified diagnosis

Conditions: Severe Pneumonia; Biomarkers

Summary: the purpose of this study is to clarify the biomarkers for rapid diagnosis and stratified diagnosis of severe respiratory tract infectious diseases through clinical experiments.

methods: the relationship between relevant biomarkers and stratified diagnosis was analyzed by collecting laboratory and etiological examinations of patients with severe pneumonia.

Eligibility criteria:
inclusion criteria: * meets the diagnostic criteria for severe pneumonia； * age≥18 years old and \< 80 years old； * willing to sign informed consent for the course of the study； exclusion criteria: * patients with intracranial hypertension, acute coronary syndrome, pleural fistula, pneumothorax, or subcutaneous emphysema; * pregnant and lactating patients; * severely hemodynamically unstable (an increase in vasopressors by more than 30% in the first 6 hours, or norepinephrine \>0.5mg/kg/min); * those who do not consent to participate in this study；
noble meta alloy coated catheters in patients with long term catheterization

Conditions: Urinary Tract Infections; Catheter Infection; Catheter-Related Infections; Infection

Summary: eighty percent of nosocomial uti caused by indwelling urinary catheters and so known-as catheter-associated uti. cauti leads to multiple local and systemic derangements such as suprapubic pain, dysuria, cystitis, pyelonephritis, septicemia, and even septic shock. this study will be conducted up on 100 patients (50 per each group) with long term catheterization to assess efficacy of noble metal alloy coated catheter in reducing cauti.

this prospective controlled randomized study conducted upon 100 patients at alexandria university hospital from 21 may 2020 to 21 december 2020. patients enrolled will be divided into two equal groups according to the urethral catheter inserted the institutional ethics committee for research approved the study. written informed consent was obtained from all participants. in addition to taking the patients' medical history and completing general and physical examinations, physicians will choose proper catheter size all perform catheterization using aseptic technique according to guidelines of proper aseptic catheterization. urologist ensures comparable catheter size and amount of balloon inflation. an aseptic non-touch technique (antt) must be used to obtain catheter specimen urine following these steps: * after catheterization apply clamp 10 cm distal to meatus then after few minutes clean the drainage port with alcohol and allow to dry then insert the syringe tip into the drainage port. * three to five ml of urine collected in sterile disposable plastic cup at day zero (within 2 hours of catheterization), day ten and day twenty post catheterization. * the urine subjected to routine urine analysis, urine culture and sensitivity. appropriate statistical tests will be used to indicate the frequency and type of cauti as well as to assess catheter tolerance in each arm, followed by a comparison to conclude the results.

Eligibility criteria:
inclusion criteria: - patient under age of 80 years old who need prolonged urethral catheterization (more than 2 weeks) as a method of bladder drainage. exclusion criteria: * patients with current or recent symptomatic urinary tract infection. * antibiotic use currently or within 7 days prior to inclusion. * known hypersensitivity to latex, silver salts or hydrogel. * patients with recent surgical intervention in the urinary tract. * patients with anatomic or functional upper urinary tract issues (e.g reflux, stones, etc.) * uncontrolled dm. patients on corticosteroid treatment. immunosuppressed patients. patients received pelvic irradiation.

Keywords: catheter uti foley catheter nobel metal alloy catheter